152 results on '"Paris, Laura"'
Search Results
2. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
3. Vector control for malaria prevention during humanitarian emergencies: a systematic review and meta-analysis
4. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
5. Foundations of hemophilia and epidemiology
6. Evaluating barriers to reaching women with public health information in remote communities in Mali.
7. Anticoagulation and Antiplatelet Regimen in Cardiac Transplant. Clinical Characteristics, Outcomes, and Blood Product Transfusion.
8. Humanistic burden of haemophilia A without inhibitors: A cross‐sectional analysis of the HemoLIFE study.
9. Evaluating barriers to reaching women with public health information in remote communities in Mali
10. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
11. A review of Musca sorbens(Diptera: Muscidae) and Musca domesticabehavior and responses to chemical and visual cues
12. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
13. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
14. P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study
15. P895: DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL
16. P883: ALNUCTAMAB (ALNUC; BMS-986349; CC-93269), A BCMA × CD3 T-CELL ENGAGER, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LATEST RESULTS FROM A PHASE 1 FIRST-IN-HUMAN CLINICAL STUDY
17. When Cannabis sativa L. Turns Purple: Biosynthesis and Accumulation of Anthocyanins
18. Treating multiple myeloma in the era of new drugs: What is the right choice?
19. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
20. Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion
21. Parasite clearance dynamics in children hospitalised with severe malaria in the Ho Teaching Hospital, Volta Region, Ghana
22. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis
23. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
24. OAB-011: Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial
25. Associated Cancers in Waldenström Macroglobulinemia: Clues for Common Genetic Predisposition
26. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
27. Vector Control for Malaria Prevention During Humanitarian Emergencies: A Systematic Review and Meta-Analysis
28. Factors Predicting Transformation of Asymptomatic IgM Monoclonal Gammopathy
29. Real-World Patterns of Utilization and Outcome of Market Approved Lenalidomide-Based Triplet Combinations in First Relapsed Multiple Myeloma Patients: Evidence from a Propensity Score Matched Analysis
30. Safety of outpatient stem cell mobilization with low‐ or intermediate‐dose cyclophosphamide in newly diagnosed multiple myeloma patients
31. Additional file 1 of Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study
32. Additional file 2 of Covid-19 and gender: lower rate but same mortality of severe disease in women—an observational study
33. A Rare Case of Atypical Palatal‐Lingual Tremor Associated with Waldenström's Macroglobulinemia
34. Body Dissatisfaction and Disordered Eating in Three Cultures: Argentina, Brazil, and the U.S.
35. Estrategias de afrontamiento del estres como potenciadoras de bienestar
36. Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use
37. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
38. Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability
39. Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
40. Newly-Diagnosed, Non-Transplant Eligible Multiple Myeloma Patients: Determinants of Choice of First-Line Treatment in a Single-Center
41. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
42. Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis
43. Introduzione
44. Anselmo Bucci, Carlo Wostry, Giuseppe Furlani: tre interpreti della 'Finis Austriae'
45. Validation of a subjective well-being inventory with youth and adolescents Argentinean, Mexican, and Brazilian Samples
46. Guida al Lascito Antonio Fonda Savio
47. Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study
48. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
49. Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis
50. Immagini di un’epoca
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.